Esperion Therapeutics Inc (ESPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Esperion Therapeutics Inc (ESPR) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.29 Million) by net assets ($-451.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ESPR market cap for the company's overall valuation and market capitalisation.
Esperion Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Esperion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Esperion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Esperion Therapeutics Inc ranked by their cash flow conversion efficiency. Explore ESPR cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Kinlong Hardware Products Co Ltd
SHE:002791
|
0.031x |
|
DNA Link Inc
KQ:127120
|
-0.060x |
|
Indian Metals & Ferro Alloys Limited
NSE:IMFA
|
0.121x |
|
Da-Cin Construction Co Ltd
TW:2535
|
0.047x |
|
Zhejiang Whyis Technology Co.Ltd.
SHE:301218
|
N/A |
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
0.042x |
|
Hefei Fengle Seed Co Ltd
SHE:000713
|
0.076x |
|
Henan Senyuan Electric Co Ltd
SHE:002358
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Esperion Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Esperion Therapeutics Inc from 1999 to 2024. View Esperion Therapeutics Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-388.72 Million | $-23.65 Million | 0.061x | -79.57% |
| 2023-12-31 | $-454.99 Million | $-135.49 Million | 0.298x | -44.85% |
| 2022-12-31 | $-323.78 Million | $-174.83 Million | 0.540x | -59.69% |
| 2021-12-31 | $-196.94 Million | $-263.81 Million | 1.340x | +51.18% |
| 2020-12-31 | $-96.13 Million | $-85.18 Million | 0.886x | +125.13% |
| 2019-12-31 | $19.95 Million | $-70.34 Million | -3.526x | -87.68% |
| 2018-12-31 | $79.12 Million | $-148.64 Million | -1.879x | -250.11% |
| 2017-12-31 | $244.69 Million | $-131.30 Million | -0.537x | -157.01% |
| 2016-12-31 | $228.60 Million | $-47.73 Million | -0.209x | -57.19% |
| 2015-12-31 | $287.26 Million | $-38.16 Million | -0.133x | +44.60% |
| 2014-12-31 | $133.55 Million | $-32.02 Million | -0.240x | +1.93% |
| 2013-12-31 | $74.09 Million | $-18.11 Million | -0.244x | -139.33% |
| 2012-12-31 | $-17.39 Million | $-10.81 Million | 0.622x | -58.49% |
| 2011-12-31 | $-6.06 Million | $-9.07 Million | 1.497x | +318.37% |
| 2002-12-31 | $38.74 Million | $-26.56 Million | -0.686x | -100.26% |
| 2001-12-31 | $66.50 Million | $-22.77 Million | -0.342x | -29.08% |
| 2000-12-31 | $67.69 Million | $-17.95 Million | -0.265x | +90.49% |
| 1999-12-31 | $2.81 Million | $-7.85 Million | -2.790x | -- |
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more